Eli Lilly has entered a $2.4 billion definitive agreement to acquire Orna Therapeutics. This strategic move integrates Orna’s proprietary circular RNA platform and in vivo CAR-T pipeline into Lilly’s growing portfolio, signaling a major shift toward more accessible and scalable genetic medicines for B cell-driven autoimmune diseases.
AbbVie has finalized its acquisition of Capstan Therapeutics, gaining access to a groundbreaking in vivo tLNP CAR-T cell therapy and proprietary RNA delivery platform for B cell-mediated autoimmune diseases.
Allogene Therapeutics, a clinical-stage biotechnology company, has selected the standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen for its ALPHA3 study.
In a breakthrough for oncology, Johnson & Johnson has announced promising early results from a Phase 1b clinical trial for its second-generation CAR T-cell therapy, [Read More…]
The researchers found that the tumor was produced by more than only the T cells’ present genetic changes.
The study discovered that the body may produce more ID3+ T cells in response to certain signals, opening the door for better therapies like CAR T cell therapy.
CAR T cell therapy allows a patient’s T cells to be reprogrammed to identify and eliminate the cancer cells
Novel immunotherapies like CAR T-cell therapies may not be effective in treating aggressive types of blood cancer due to a unique mutation in the cancer cells.
